Brii Biosciences Limited

SEHK:2137 Stock Report

Market Cap: HK$621.5m

Brii Biosciences Past Earnings Performance

Past criteria checks 0/6

Brii Biosciences has been growing earnings at an average annual rate of 41.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 15.3% per year.

Key information

41.3%

Earnings growth rate

60.6%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate-15.3%
Return on equity-9.6%
Net Margin-691.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12
Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24
We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Revenue & Expenses Breakdown

How Brii Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2137 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2438-265205327
31 Mar 2447-220202365
31 Dec 2356-175198403
30 Sep 2395-251193394
30 Jun 23134-327189384
31 Mar 23128-405192412
31 Dec 22122-484195441
30 Sep 2299-1,021223518
30 Jun 2275-1,558251595
31 Mar 2284-2,861230545
31 Dec 2193-4,164208495
30 Sep 21100-3,999169631
30 Jun 21107-3,835130768
31 Mar 2194-2,512117822
31 Dec 2082-1,190103876
31 Dec 1920-5216384

Quality Earnings: 2137 is currently unprofitable.

Growing Profit Margin: 2137 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2137 is unprofitable, but has reduced losses over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare 2137's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2137 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).

Return on Equity

High ROE: 2137 has a negative Return on Equity (-9.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:37
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Geoffrey PorgesLeerink Partners LLC